Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 20/20 | 0.75 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.58 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625848 | 0.92 | PTK2 (0.76) | PTK2 | |
| SCHEMBL14931459 | 0.92 | PTK2 (0.75) | PTK2PTK2BJAK2NTRK1TYK2 | |
| SCHEMBL14931470 | 0.89 | PTK2 (0.73) | PTK2PTK2BJAK2NTRK1TYK2 | |
| SCHEMBL14931201 | 0.88 | PTK2 (0.75) | PTK2PTK2B | |
| SCHEMBL14931304 | 0.87 | PTK2 (0.78) | PTK2PTK2B | |
| SCHEMBL14931400 | 0.87 | PTK2 (0.76) | PTK2PTK2B | |
| SCHEMBL14931372 | 0.87 | PTK2 (0.74) | PTK2PTK2BJAK2NTRK1TYK2 | |
| SCHEMBL14931383 | 0.87 | PTK2 (0.76) | PTK2PTK2B | |
| SCHEMBL1627144 | 0.86 | PTK2 (1.00) | PTK2PTK2B | |
| SCHEMBL29853567 | 0.86 | PTK2 (1.00) | PTK2PTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440822-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. | 2013-05-14 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |